Calliditas Therapeutics AB (publ)
CLTEF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -10.36 | 0.00 | 0.13 |
| FCF Yield | -0.45% | -0.14% | -0.01% | -0.36% |
| EV / EBITDA | -349.87 | 2,969.13 | -2,466.49 | -71.43 |
| Quality | ||||
| ROIC | -4.00% | -3.26% | -0.06% | -2.66% |
| Gross Margin | -14,236.91% | 0.00% | 0.00% | 90.45% |
| Cash Conversion Ratio | 1.52 | -5.74 | 0.05 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 84.42% | 123.99% | 223.99% | 228.47% |
| Free Cash Flow Growth | -94.70% | -212.10% | 0.00% | 96.45% |
| Safety | ||||
| Net Debt / EBITDA | 4.39 | 0.80 | -1,586.98 | -6.93 |
| Interest Coverage | -509.55 | -421.43 | -5,098.77 | -2.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 1.33 |
| Cash Conversion Cycle | 4,852.11 | -870.35 | -14.37 | -150.87 |